Rachel W. Vojvodic

发表

A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF trial

Mohammad R. Ostovaneh, Doris A Taylor, B. Davis, 2021, European journal of heart failure.

Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.

Doris A Taylor, B. Byrne, D. Gordon, 2011, JAMA.

Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.

Doris A Taylor, D. Gordon, T. Henry, 2012, JAMA.

Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells).

Doris A Taylor, S. Berceli, J. Lima, 2017, Circulation.

Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells.

Doris A Taylor, J. Lima, T. Henry, 2014, American heart journal.

Emergency Room Use and Access to Primary Care: Evidence from Houston, Texas

C. Begley, K. Burau, Rachel W. Vojvodic, 2006, Journal of health care for the poor and underserved.

Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale.

Doris A Taylor, T. Henry, S. Ellis, 2011, American heart journal.

Recommendations for Nomenclature and Definition Of Cell Products Intended for Human Cardiovascular Use.

Doris A Taylor, T. Henry, Phillip C. Yang, 2021, Cardiovascular research.

Recruiting for Acute Myocardial Infarction Cell Therapy Trials: Challenges and Best Practices for the CCTRN.

Doris A Taylor, T. Henry, E. Handberg, 2014, Clinical researcher.

Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.

Doris A Taylor, B. Byrne, D. Gordon, 2009, American heart journal.

Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit+ Cardiac Stem Cells As Regenerative Therapy for Heart Failure)

Doris A Taylor, J. Lima, T. Henry, 2018, Circulation research.

Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.

Dejian Lai, Saif Anwaruddin, Catalin Loghin, 2012, JAMA.

LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.

Doris A Taylor, B. Byrne, D. Gordon, 2010, Texas Heart Institute journal.

Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients

Mohammad R. Ostovaneh, Doris A Taylor, B. Davis, 2020, JACC. CardioOncology.

Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial

J. Lima, T. Henry, Phillip C. Yang, 2018, American heart journal.

Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN).

D. Gordon, T. Henry, J. Cooke, 2013, Circulation.

Implementation of Cardovascular Cell Therapy Network trials: challenges, innovation and lessons learned from experience in the CCTRN

T. Henry, C. Pepine, E. Perin, 2013, Expert review of cardiovascular therapy.

Controlled, Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells 2 to 3 Weeks after Acute Myocardial Infarction

Doris A Taylor, B. Byrne, T. Henry, 2010 .

Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design.

B. Byrne, D. Gordon, T. Henry, 2010, American heart journal.

Reliability and Validity of a Questionnaire to Measure Colorectal Cancer Screening Behaviors: Does Mode of Survey Administration Matter?

Maria E Fernandez, Jasmin A. Tiro, S. Vernon, 2008, Cancer Epidemiology Biomarkers & Prevention.

Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.

Doris A Taylor, B. Byrne, D. Gordon, 2009, American heart journal.

Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells.

B. Venkatesh, E. Perin, N. Leeper, 2014, American heart journal.